SLC5A2 and diabetes mellitus: The phase 3 DINAMO (Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents) trial, which assessed the efficacy of empagliflozin (an SGLT-2 inhibitor) and linagliptin (a DPP-4 inhibitor) in youth with T2D, assessed safety only until week 52 (21), again highlighting the previous lack of investigation into the longer-term safety of T2D treatment in children and adolescents after treatment withdrawal.